Navigation Links
Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors

BROOMFIELD, Colo., March 24 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today that Thomas Werner, Ph.D. has been elected to its board of directors.

Since 2001, Dr. Werner has been a managing director and senior vice president of GlaxoSmithKline (GSK) and has served as CEO of the GSK Foundation until earlier this year. He led the Pharmaceutical Research Manufacturers of America (PhRMA) in Germany as its chairman through November 2008. He began his pharmaceutical career with Squibb Pharma Germany where he held sales, marketing and brand management positions from 1983-1989 and later held executive management positions at Bristol-Myers Squibb. Dr. Werner earned his Ph.D. in chemistry at the University of Gottingen in Germany.

Dr. Werner was instrumental in the successful growth strategies and leadership of the German subsidiaries of GSK and Bristol-Myers Squibb. He grew sales of the ACE inhibitor, Captopril, to become the largest pharmaceutical product in Germany, and developed Viani, an asthma drug, into one of the leading pharmaceutical products in Germany.

Dr. Werner co-founded the Genetic Research Center, a joint venture with the Max Planck Institute for Psychiatry and the Ludwig-Maximilians-University, both in Munich. He is a member of the Board of Trustees of the Paul Ehrlich Association and the Robert Koch Foundation.

"We are delighted to welcome Dr. Werner to our board of directors," said Steve Orndorff, Ph.D., Accera's founder and CEO. "Thomas has a demonstrated record of success in the management and leadership of European subsidiaries of internationally acclaimed pharmaceutical companies. With Accera's recent US product launch of Axona(TM) for Alzheimer's disease, Dr. Werner's experience in the commercialization of several highly successful drug products will be invaluable."

About Accera, Inc.

Accera, Inc., a privately held biotechnology company, discovers and develops therapeutic breakthroughs in central nervous systems disorders. Accera's novel approaches positively impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, Accera is developing products that address metabolic deficiencies associated with certain neurodegenerative diseases by providing an alternative energy source for the brain. For more information, visit

    Contacts:                              Richard Lewis Communications, Inc.
    Accera, Inc.                           (212) 827-0020
    (303) 999-3710                         Gregory Tiberend, Media
    Steve Orndorff, Ph.D.        
    Founder, President and CEO             Cecelia Heer, Investors    

SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
2. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
3. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
4. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
5. eResearchTechnology, Inc. to Present at the Thomas Weisel Healthcare Conference on September 4th, 2008
6. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Conference
8. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
9. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
10. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
11. Volcano Presentation at Thomas Weisel Conference to Be Webcast
Post Your Comments:
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... HART ), a biotechnology company developing bioengineered organ implants ... McGorry will present at the LD Micro "Main ... 2:30 p.m. PT. The presentation will be webcast live ... Management will also be available at the conference for ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/25/2015)... Francisco, CA (PRWEB) , ... November 25, 2015 ... ... microbial genomics company uBiome, were featured on AngelList early in their initial angel ... launching an AngelList syndicate for individuals looking to make early stage investments in ...
Breaking Biology Technology:
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
(Date:10/26/2015)... PALO ALTO, Calif. and LAS ... – Nok Nok Labs , an innovator in ... FIDO Alliance , today announced the launch of its ... the first unified platform enabling organizations to use standards-based ... authentication. The Nok Nok S3 Authentication Suite is ideal ...
Breaking Biology News(10 mins):